These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 2324496)

  • 21. Fluorescence resonance energy transfer study of the associative state of membrane-bound complexes of complement proteins C5b-8.
    Cheng KH; Wiedmer T; Sims PJ
    J Immunol; 1985 Jul; 135(1):459-64. PubMed ID: 3923109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Homologous restriction factor: effect on complement C8 and C9 uptake and lysis.
    Zalman LS; Müller-Eberhard H
    Mol Immunol; 1994 Mar; 31(4):301-5. PubMed ID: 8139583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced expression of the complement-regulatory factor C8 binding protein (C8bp) on U937 cells after stimulation with IL-1 beta, endotoxin, IFN-gamma, or phorbol ester.
    Schieren G; Janssen O; Hänsch GM
    J Immunol; 1992 May; 148(10):3183-8. PubMed ID: 1578143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional studies of the MACPF domain of human complement protein C8alpha reveal sites for simultaneous binding of C8beta, C8gamma, and C9.
    Slade DJ; Chiswell B; Sodetz JM
    Biochemistry; 2006 Apr; 45(16):5290-6. PubMed ID: 16618117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Homologous species restriction in the complement mediated cytolysis and its mechanism].
    Zhang Y; Zhou FL
    Sheng Li Ke Xue Jin Zhan; 1991 Jul; 22(3):231-4. PubMed ID: 1947984
    [No Abstract]   [Full Text] [Related]  

  • 26. On the cause and nature of C9-related heterogeneity of terminal complement complexes generated on target erythrocytes through the action of whole serum.
    Bhakdi S; Tranum-Jensen J
    J Immunol; 1984 Sep; 133(3):1453-63. PubMed ID: 6747293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. C5b-9 assembly: average binding of one C9 molecule to C5b-8 without poly-C9 formation generates a stable transmembrane pore.
    Bhakdi S; Tranum-Jensen J
    J Immunol; 1986 Apr; 136(8):2999-3005. PubMed ID: 3958488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of a disulfide-bonded peptide loop within human complement C9 in the species-selectivity of complement inhibitor CD59.
    Husler T; Lockert DH; Sims PJ
    Biochemistry; 1996 Mar; 35(10):3263-9. PubMed ID: 8605162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Species-restricted target cell lysis by human complement: complement-lysed erythrocytes from heterologous and homologous species differ in their ratio of bound to inserted C9.
    Hu VW; Shin ML
    J Immunol; 1984 Oct; 133(4):2133-7. PubMed ID: 6470486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mapping of the complement C9 binding domain in paramyosin of the blood fluke Schistosoma mansoni.
    Deng J; Gold D; LoVerde PT; Fishelson Z
    Int J Parasitol; 2007 Jan; 37(1):67-75. PubMed ID: 17123534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Function of subunits within the eighth component of human complement: selective removal of the gamma chain reveals it has no direct role in cytolysis.
    Brickner A; Sodetz JM
    Biochemistry; 1984 Feb; 23(5):832-7. PubMed ID: 6712927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.
    Meri S; Morgan BP; Davies A; Daniels RH; Olavesen MG; Waldmann H; Lachmann PJ
    Immunology; 1990 Sep; 71(1):1-9. PubMed ID: 1698710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The membrane attack mechanism of complement: photolabeling reveals insertion of terminal proteins into target membrane.
    Hu VW; Esser AF; Podack ER; Wisnieski BJ
    J Immunol; 1981 Jul; 127(1):380-6. PubMed ID: 7240749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct restriction of complement- and cell-mediated lysis.
    Hollander N; Shin ML; Rosse WF; Springer TA
    J Immunol; 1989 Jun; 142(11):3913-6. PubMed ID: 2785570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal antibodies directed against human C5 and C8 block complement-mediated damage of xenogeneic cells and organs.
    Rollins SA; Matis LA; Springhorn JP; Setter E; Wolff DW
    Transplantation; 1995 Dec; 60(11):1284-92. PubMed ID: 8525523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Binding of human and rat CD59 to the terminal complement complexes.
    Lehto T; Morgan BP; Meri S
    Immunology; 1997 Jan; 90(1):121-8. PubMed ID: 9038722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transmembrane channel-formation by five complement proteins.
    Müller-Eberhard HJ
    Biochem Soc Symp; 1985; 50():235-46. PubMed ID: 2428370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
    Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
    J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Purification of 1F5 antigen that prevents complement attack on homologous cell membranes.
    Harada R; Okada N; Fujita T; Okada H
    J Immunol; 1990 Mar; 144(5):1823-8. PubMed ID: 2307842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular mechanisms of cytotoxicity: comparison of complement and killer lymphocytes.
    Müller-Eberhard HJ; Zalman LS; Chiu FJ; Jung G; Martin DE
    J Rheumatol Suppl; 1987 Jun; 14 Suppl 13():28-34. PubMed ID: 3612651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.